Breast cancer is a complex disease shaped by a combination of genetic predispositions, hormonal influences, environmental and lifestyle factors. With age and family history playing significant roles in determining individual patient risk, the disease remains a major healthcare challenge, affecting thousands of women across Switzerland each year.1,2
Breast Cancer in Switzerland in Numbers
~6800
80%
86%
6%
18/ 26
Early Detection & Screening
Finding breast cancer early can improve outcomes. Organised screening programmes in Switzerland help women access regular mammograms:4,7
- Regular invitations – Eligible women are invited for screening, rather than having to arrange it themselves.
- Independent review – Two radiologists read each mammogram to support consistent quality.
- Lower out-of-pocket cost – The health insurance deductible does not apply. Women pay only the 10% co-payment, usually around CHF 20.
Switzerland is lagging behind on access
Unlike many European countries with nationwide organised screening, Switzerland has no nationwide programme. Availability depends on the canton: 18 of 26 currently offer a programme for women aged 50 and over.5,6,8
New Survey: Screening Awareness & Barriers
A new representative survey conducted by the independent market research institute YouGov on behalf of AstraZeneca Switzerland found that 98% of the 1’506 women aged 49–75 surveyed knew that breast cancer screening programmes exist.
Yet awareness did not always lead to regular participation: 62% reported being screened in the past two years, while 35% had been screened at least twice through an organised programme.9
Women’s responses point to several reasons for irregular participation rates:
- Concerns about pain and false-positive results can make screening feel daunting.
- Uncertainty about costs and eligibility can make it harder to decide.
- Inconsistent advice from doctors can leave women without clear guidance.
Clearer information, proactive doctor-patient conversations, and timely reminders can help bridge this gap, supporting women in making informed choices about their health.5
Our stories of progress in cancer care
For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch
References
- Pasi D, Aswathy B, Das M, Agrawal P. Front Oncol. 2026;16:1773232.
- Diagnose und Therapie von Brustkrebs in der Schweiz; Erkenntnisse und Handlungsbedarf auf Basis von Daten aus der Krebsregistrierung 2020–2022. Nationale Krebsregistrierungsstelle (NKRS) Zürich, Oktober 2025. Available at: https://www.nkrs.ch/upload/downloads/Berichte%20und%20Statistiken/KennzahlenZuDiagnoseUndTherapie/Summary_BreastCancerIndicators_2020-2022_DE.pdf. Last accessed: September 2026.
- Donna Programm. Brustkrebs-Früherkennung durch Mammographie. Available at: www.donna-programm.ch/fileadmin/data/downloads/de-downloads/donna-informationsbroschuere-de.pdf. Last accessed: September 2026.
- Effects of age and stage on breast cancer survival in Switzerland. Schweizer Krebsbulletin. Available at: https://www.nicer.org/assets/files/publications/others/skb_2-2015_breastcancer_survival_ch.pdf. Last accessed: September 2026.
- Pink Cube. Early Detection. Available at: https://pinkcube-testyourbreast.ch/en/early-detection/. Last accessed: September 2026.
- Swiss Cancer Screening. Krebsfrüherkennungsprogramme in Ihrer Region. Available at: https://www.swisscancerscreening.ch/de/angebote-in-ihrem-kanton. Last accessed: September 2026.
- Swiss Cancer Screening. Teilnahme an einem Programm zur Brustkrebsfrüherkennung. Available at: https://www.swisscancerscreening.ch/de/krebs-frueherkennung/brust/teilnahme. Last accessed: September 2026.
- OECD Health Policy Studies. Beating Cancer Inequalities in the EU. Available at: https://health.ec.europa.eu/system/files/2024-01/ncd_cancer-inequalities_report_en.pdf. Last accessed: September 2026.
- YouGov survey commissioned by AstraZeneca Switzerland; 1’506 women aged 49–75 in German-, French- and Italian-speaking Switzerland, June–July 2026.
Veeva ID: CH-13787
Date of preparation: October 2026